Insulet | PODD - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Abbott USD 6.65B 787M 2026-06
Align Technology USD 757.43M 20.84M 2026-06
AtriCure USD 109.31M 3.97M 2026-03
Baxter International USD 1.14B 251M 2026-06
Becton, Dickinson and Co. USD 2.32B 161M 2026-06
Boston Scientific USD 3.82B 210M 2026-06
Cardinal Health USD 2.56B 62M 2026-06
Cooper Companies USD 711.9M 23.5M 2026-06
Dexcom USD 750.3M 42.4M 2026-03
Edwards Lifesciences USD 1.35B 62.6M 2026-06
Eli Lilly USD 16.22B 301.7M 2026-03
Globus Medical USD 548.17M 51.91M 2026-06
ICU Medical USD 235.05M 28.83M 2026-06
Inogen USD 41.34M 1.39M 2024-09
Insulet USD 562.6M 21.8M 2026-06
Integra LifeSciences USD 215.97M 2.77M 2026-06
J&J USD 18.55B 1.31B 2026-06
Medtronic USD 6.36B 355M 2026-06
Merit Medical Systems USD 215.17M 30.37M 2026-06
Roche Holding CHF 22.69B 600M 2026-06
Solventum Corp USD 1.29B 189M 2026-06
Stryker USD 4.5B 688M 2026-06
Tandem Diabetes Care USD 144.78M 7.99M 2026-06
Teleflex USD 331.71M 24.28M 2026-06
West Pharmaceutical Services USD 296.4M 7.5M 2026-03
Zimmer Biomet Holdings USD 1.36B 149.4M 2026-06